Oxford Expression Technologies Launches VLP Vaccine Production Services Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, now applies its expertise to the production of recombinant vaccines, particularly in the field of virus like particle (VLP) vaccines. Oxford, UK, June 15, 2011 - Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, now applies its expertise to the production of recombinant vaccines, particularly in the field of virus like particle (VLP) vaccines. VLP vaccines represent the next generation of treatment methodologies; the VLP platform offers huge potential for use as a highly effective antiviral vaccine. The secret to virus like particle vaccines is their ability to mimic the structure of a real virus. After vaccination with these mimics, an individualâ€™s immune response reacts largely as it would to the real virus, but due to the absence of genetic material the VLP vaccine is unable to replicate and is therefore harmless to the vaccinated individual. VLP production requires high yields of multiple virus structural proteins to form complex structures. The expression system needed to produce these structures must be both safe and capable of producing proteins both on a small (testing) and large scale (vaccine production). These requirements are ideally suited to Oxford Expression Technologies highly efficient and scalable baculovirus protein expression system (flashBAC). Passing comment, Richard Broadhead, Sales and Marketing Manager at Oxford Expression Technologies said, "Baculovirus Expression systems overcome many of the problems associated with VLP production, the FDA has recently licensed a baculovirus produced VLP vaccine for use in
humans (CervarixÂŽ by GlaxoSmithKline), paving the way for further baculovirus based VLP production," he continued, "Oxford Expression Technologies is uniquely placed to apply its existing baculovirus expertise to this exciting new field of virus like particle vaccines." Oxford Expression Technologies invites anyone with an interest in VLP vaccines to please visit their website - http://oetltd.com/articles/newspress/news-stories/vaccine-vlp.html Oxford Expression Technologies is a biotechnology company specializing in the use of baculovirus vectors, a eukaryotic expression system that can express a large variety of recombinant proteins. Oxford Expression Technologies provides protein expression products, services and consultancy to many global pharmaceutical companies. The Companyâ€™s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. Its internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus expression systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease. The company was founded in 2007 as a result of collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes. For Further information or an illustrative image: Media contact - Mathew Taylor, Director, Algorythm Solutions Ltd, mobile: +44 (0)773 403 2112, email: email@example.com, website: www.algorythmsolutions.com Contact: Mathew Taylor Director Algorythm Solutions Ltd 10 Torkington St Stamford, Lincolnshire PE9 2UY +44 (0)773 403 2112 firstname.lastname@example.org http://www.algorythmsolutions.com
Published on Jun 16, 2011
Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, now applies its exp...